Filtered By:
Drug: Herceptin
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applications
Immunol Res. 2023 Aug 26. doi: 10.1007/s12026-023-09418-9. Online ahead of print.ABSTRACTIn the past decade, various single-domain antibodies from llamas, also known as VHH or nanobody, have been discovered with applications in tumor imaging and cancer therapy. However, the potential application of anti-HER2 VHHs as a diagnostic tool suitable for ELISA, flow cytometry, cell imaging, bispecific antibody engineering, and immunohistochemistry has not been fully elucidated. To investigate this potential, HER2 antigen was expressed in HEK293 F cells, purified, and used to immunize llama. Using phage display, anti-HER2 VHHs with...
Source: Cell Research - August 26, 2023 Category: Cytology Authors: Shahryar Khoshtinat Nikkhoi Hediyeh Heydarzadeh Venu Gopal Vandavasi Ge Yang Pedro Louro Marianne Polunas Hajar Owji Arash Hatefi Source Type: research
Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients
CONCLUSIONS: In patients with breast cancer, there is progression of endothelial dysfunction and arteriosclerosis up to 15 months following initiation of anthracycline-based chemotherapy. Trastuzumab has no additive effect on endothelial function or arterial stiffness.PMID:37455009 | DOI:10.1016/j.vph.2023.107195
Source: Vascular Pharmacology - July 16, 2023 Category: Drugs & Pharmacology Authors: Maria Anastasiou Evangelos Oikonomou Panagiotis Theofilis George Angelos Papamikroulis Maria Gazouli Konstantinos Kalogeras Stavroula Lygkoni Theodoros Pesiridis Athina Goliopoulou Alkistis Papatheodoridi Amanda Psyrri Flora Zagouri Gerasimos Siasos Dimit Source Type: research
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions
JCO Oncol Pract. 2023 Jul 14:OP2300227. doi: 10.1200/OP.23.00227. Online ahead of print.ABSTRACTCancer therapy has environmental costs. In this simulation analysis, @garthstrohbehn and colleagues show how less frequent dosing and shorter durations of therapy might improve public health without making patients with cancer worse off.PMID:37450776 | DOI:10.1200/OP.23.00227
Source: Ann Oncol - July 14, 2023 Category: Cancer & Oncology Authors: Sofia I Jacobson Alec J Kacew Randall W Knoebel Po-Hung Hsieh Mark J Ratain Garth W Strohbehn Source Type: research
Comparing Renin-Angiotensin-Aldosterone Blockade Regimens for Long-Term Chemotherapy-Related Cardiac Dysfunction: A Network Meta-Analysis
ConclusionNineteen studies reported the effects of 13 interventions (N = 1905 patients). Only enalapril (RR 0.05, 95% CI 0.00 –0.20) was associated with reduced risk of patients developing significant decline in LVEF relative to placebo. Subgroup analysis showed that the beneficial effect of enalapril was driven by protection against anthracycline-associated toxicity. In addition, no RAAS-inhibiting agents showed efficac y in protection against treatment with both anthracycline and trastuzumab. The use of RAAS inhibition therapy did not conclusively impact on other markers of cardiac function, including left ventricular ...
Source: Cardiovascular Drugs and Therapy - June 14, 2023 Category: Cardiology Source Type: research
Rise of Antibody-Drug Conjugates: The Present and Future
Am Soc Clin Oncol Educ Book. 2023 May;43:EDBK39009. doi: 10.1200/EDBK_390094.ABSTRACTAntibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy-the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells-so-called smart chemo. Although there were significant challenges in achieving this milestone culminating in the first Food and Drug Administration approval in 2000, subsequent advancements in technology have led to rapid drug development with regulatory approvals for ADCs targeting a variety of tumor types. The most successful application for solid tumors has be...
Source: Clinical Genitourinary Cancer - May 25, 2023 Category: Cancer & Oncology Authors: Mythili Shastry Avantika Gupta Sarat Chandarlapaty Matthew Young Thomas Powles Erika Hamilton Source Type: research
Development, efficacy and side effects of antibody ‑drug conjugates for cancer therapy (Review)
Mol Clin Oncol. 2023 May 4;18(6):47. doi: 10.3892/mco.2023.2643. eCollection 2023 Jun.ABSTRACTAntibody-drug conjugates (ADCs) are anticancer drugs that combine cytotoxic small-molecule drugs (payloads) with monoclonal antibodies through a chemical linker and that transfer toxic payloads to tumor cells expressing target antigens. All ADCs are based on human IgG. In 2009, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin as the initial first-generation ADC. Since then, at least 100 ADC-related projects have been initiated, and 14 ADCs are currently being tested in clinical trials. The limited success of g...
Source: Clinical Genitourinary Cancer - May 19, 2023 Category: Cancer & Oncology Authors: Te Sun Xueli Niu Qing He Min Liu Shuai Qiao Rui-Qun Qi Source Type: research
